Alector Inc. (ALEC) unveiled a restructured drug pipeline at the Morgan Stanley 24th Annual Global Healthcare Conference on September 15, marking a decisive shift from late-stage clinical programs to five pre-clinical candidates focused on brain delivery.
CEO Arnon Rosenthal said the company is no longer the Phase III organization it once was, having abandoned its earlier hypothesis centered on brain-specific immune checkpoints. The new strategy emphasizes enzyme replacement, siRNA therapeutics, and misfolded protein inhibition, all built around the Alector Brain Carrier (ABC) platform developed over more than seven years.
The ABC platform transports medicines across the blood-brain barrier via transferrin receptor-mediated transport and is capable of delivering antibodies, enzymes, RNA, and siRNAs. In non-human primate studies, the platform showed high-dose tolerance up to 250 mg/kg without hematologic effects and several-fold higher brain exposure than competing brain-shuttle approaches at single-digit milligram subcutaneous doses.
Lead asset AL137, a brain-enabled anti-pyroglutamate amyloid-beta antibody, is designed for monthly subcutaneous injection at single-digit milligram doses. Healthy-volunteer dosing is expected in the second quarter of 2027, with patient dosing following shortly after. A biomarker and safety package is anticipated by end of 2027 or early 2028. Rosenthal noted the asset targets the same pyroglutamate epitope as Donanemab but aims to reduce amyloid-related imaging abnormalities compared with Gantenerumab, and differs in target biology from Lecanemab.
Other pipeline assets include AL164, a tau siRNA with stronger chemical stability than its predecessor AL064; non-human primate data showed more than 70% knockdown of tau mRNA after subcutaneous dosing with effects lasting at least three months. AL050, a GCase enzyme replacement, demonstrated 50-fold higher activity and 50-fold greater stability than the native enzyme, with non-human primate studies showing a 100% increase in brain enzymatic activity and no hematologic findings; IND-enabling work is ongoing. An alpha-synuclein siRNA program targeting Parkinson's disease and Lewy body dementia showed 94% mRNA knockdown with subcutaneous delivery.
Financially, Alector carries approximately $170 million in cash, management stated the balance provides sufficient runway through 2027 and into early proof-of-concept readouts in patients. The stock rose $0.07, or 3.27%, to $2.21 on Tuesday, giving the company a market capitalization of $247 million. Revenue fell 83% over the trailing twelve months. The company also reported a current ratio of 5.26.
Rosenthal acknowledged that some investors continue to penalize the stock because of its past portfolio but argued the current pipeline is fundamentally different. The company has implemented workforce reductions while keeping core R&D functions in-house and is utilizing AI across regulatory filing support, contract review, clinical trial design, and operations. "At this point, I think it's fair to say that actual drug discovery, like actual innovation, is still not there for AI," Rosenthal said, emphasizing that human scientists still drive target selection.
Alector has held extensive interactions with the FDA via INTERACT and pre-IND meetings, relying on tools established under the FDA Modernization Act to reduce animal usage, shorten toxicity studies, and lean more heavily on surrogate biomarkers including Amyloid PET imaging, serum and CSF markers such as p-tau217 and Abeta 40/42, Tau PET imaging, and phospho-tau measurements.
The company confirmed that its collaboration with GSK is winding down. Eric Brown, senior director of antibody discovery and protein engineering, stressed the depth of the ABC platform's development history in response to investor questions about the company's reset.
